文献速递泌尿男性生殖肿瘤

阿昔替尼联合依维莫司治疗转移性实体瘤的I期研究及肾细胞癌扩展结果:EVAX研究

Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.
PubMed 文献 · Eur J Cancer · 2017-09-05

EVAX是一项I期剂量递增研究,评估阿昔替尼联合依维莫司在晚期实体瘤中的安全性,并扩展至初治转移性肾细胞癌。15例患者入组三个剂量水平,DL2为最大耐受剂量,推荐II期剂量为阿昔替尼5mg每日两次联合依维莫司10mg每日一次。扩展期初治MRCC中5例部分缓解、1例延长疾病稳定。

要点

  • 推荐II期剂量为阿昔替尼5mg每日两次联合依维莫司10mg每日一次。
  • DL0报告1例剂量限制性毒性(III级腹泻),DL2报告1例剂量限制性毒性(III级乏力)。
  • 扩展期初治MRCC中5例部分缓解、1例延长疾病稳定。

核心结论

  • 推荐II期剂量为阿昔替尼5mg每日两次联合依维莫司10mg每日一次。

研究设计与样本

  • I期剂量递增研究,纳入15例晚期实体瘤患者,探索阿昔替尼联合依维莫司的安全性,并进行药代动力学和功能性血管成像。
  • 研究包含三个剂量水平:DL0为阿昔替尼3mg每日两次/依维莫司5mg每日一次;DL1为阿昔替尼5mg每日两次/依维莫司5mg每日一次;DL2为阿昔替尼5mg每日两次/依维莫司10mg每日一次,周期28天。
  • 扩展期纳入初治转移性肾细胞癌患者,按最大耐受剂量治疗。

主要发现

  • DL0报告1例剂量限制性毒性(III级腹泻),DL2报告1例剂量限制性毒性(III级乏力)。
  • 两例患者发生3起意外严重不良事件:下颌骨坏死、复发性肾功能衰竭和心肌病。
  • 最大耐受剂量为DL2;第一周期后,关注的III级或II级不良事件主要为乏力、腹泻和厌食。
  • 除1例外所有患者均出现肿瘤缩小;递增期1例膀胱癌和1例一线MRCC患者达到部分缓解。
  • 扩展期初治MRCC按最大耐受剂量治疗,5例达到部分缓解,1例为延长疾病稳定。

关键数值与推荐

  • 推荐II期剂量:阿昔替尼5mg每日两次/依维莫司10mg每日一次。
  • DL0:阿昔替尼3mg每日两次/依维莫司5mg每日一次;DL1:阿昔替尼5mg每日两次/依维莫司5mg每日一次;DL2:阿昔替尼5mg每日两次/依维莫司10mg每日一次,周期28天。
  • DL0出现1例III级腹泻剂量限制性毒性,DL2出现1例III级乏力剂量限制性毒性。

临床怎么用

  • 对于晚期实体瘤,阿昔替尼联合依维莫司的推荐II期剂量为阿昔替尼5mg每日两次联合依维莫司10mg每日一次。
  • 治疗第一周期后需关注乏力、腹泻和厌食等不良事件。
  • 扩展期初治转移性肾细胞癌患者按最大耐受剂量治疗观察到部分缓解。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anti-angiogenic and mammalian target of rapamycin inhibitors have shown efficacy in solid tumours. Reported combination of both drugs was deemed to be too toxic. Due to a potential favourable safety profile of axitinib (AX), a phase I study combining everolimus (EV) and AX for solid tumours was explored. EXPERIMENTAL DESIGN: Patients (pts) with advanced cancers were enrolled in an escalation phase I study to investigate the safety of the combination. Pharmacokinetic profile and functional vascular imaging were performed. An extension to pts with naive metastatic renal cell carcinoma (MRCC) was explored. RESULTS: 15 pts were included over three different dose levels (DLs); DL 0: AX 3 mg BID (twice daily)/EV 5 mg OD (once daily); DL 1: AX 5 mg BID/EV 5 mg OD and DL 2: AX 5 mg BID/EV 10 mg OD for 28 d. One dose-limiting toxicity (DLT) was reported at DL 0: grade (Gr) III diarrhoea and one DLT at DL 2: Gr III asthenia. Three severe adverse events (AEs) in two pts were unexpected: jaw osteonecrosis, recurrent renal failure and cardiomyopathy. Maximum tolerated dose (MTD) was level 2. After 1st cycle, Gr III or Gr II AEs of interest were mainly asthenia, diarrhoea and anorexia. All pts but one showed tumour shrinkage. Partial responses (PRs) were seen in one pt with bladder carcinoma and in one pt in 1st line MRCC in the escalating phase. In the extension phase in naive MRCC treated at MTD, five pts had a PR and one pt had a prolonged stable disease. CONCLUSION: The recommended dose for phase II is AX 5 mg BID/EV 10 mg OD.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ravaud A, Gomez-Roca C, Picat MQ, et al. Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. Eur J Cancer. 2017. PMID: 28886476. doi:10.1016/j.ejca.2017.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。